Free trade agreement between EU and Vietnam to open up new possibilities for pharma

11 August 2015

A new free trade agreement has been implemented between the European Union and Vietnam, with pharmaceuticals representing one of the key export products from the EU to Vietnam.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) considers that an eventual free trade agreement will benefit Vietnamese patients significantly, and will boost innovation and research.

It took two and a half years of negotiations to come to the agreement in principle, and the EFPIA anticipates that it will offer EU-based pharma manufacturers a level playing field in Vietnam. An agreement of this nature would also promote wider and faster patient access too innovative medicines in Vietnam.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK